New CEO as Novartis bids for growth

ReutersNewsPublished: September 4, 2017
Published: September 4, 2017

Novartis changes leadership as CEO Joseph Jimenez announces his 2018 retirement in favour of chief drug developer Vasant Narasimhan. As Ciara Lee reports, Novartis has been criticised for missing the first wave of promising cancer immunotherapy drugs and billions in sales.

Be the first to suggest a tag